Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SHP-2 and myeloid malignancies.

Marco Tartaglia1, Charlotte M Niemeyer, Kevin M Shannon

  • 1Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Rome, Italy. mtartaglia@iss.it

Current Opinion in Hematology
|December 17, 2003
PubMed
Summary

Gain-of-function mutations in SHP-2 (Src-homology 2 domain-containing protein tyrosine phosphatase) drive cancer by up-regulating RAS signaling. These mutations are implicated in myeloid malignancies and developmental disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive short stature in Pearson syndrome and the impact of organ failure.

Molecular genetics and metabolism·2026
Same author

High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia.

Nature genetics·2026
Same author

Efficacy of azacitidine and trametinib against leptomeningeal melanosis associated with congenital melanocytic nevus syndrome.

Molecular and cellular pediatrics·2026
Same author

Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years.

Blood advances·2026
Same author

Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive 'real-world routine'.

British journal of haematology·2026
Same author

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Blood cancer discovery·2025

Area of Science:

  • Molecular Biology
  • Oncology
  • Hematology

Background:

  • SHP-2 is a non-receptor protein tyrosine phosphatase crucial for signal transduction.
  • It plays vital roles in cellular processes including hematopoiesis and development.

Purpose of the Study:

  • To review the role of SHP-2 in signal transduction, hematopoiesis, and leukemogenesis.
  • To discuss the impact of SHP-2 gain-of-function mutations in human diseases, particularly myeloid malignancies.

Main Methods:

  • Literature review focusing on SHP-2 function and mutations.
  • Analysis of existing data on PTPN11 mutations in various cancers.

Main Results:

  • SHP-2 gain-of-function mutations lead to hyperactive RAS signaling.

Related Experiment Videos

  • This aberrant signaling drives the uncontrolled growth of malignant myeloid cells.

    • Conclusions:

    • SHP-2 is essential for normal development and hematopoiesis.
    • Gain-of-function mutations in PTPN11 are linked to Noonan syndrome, developmental disorders, and myeloid malignancies.
    • Further research is ongoing to define the full spectrum of PTPN11 mutations in hematologic and other cancers.